New product for brow furrows launched in the US and the UK
This article was originally published in Scrip
Medicis has launched Dysport (abobotulinumtoxinA) in the US for the treatment of glabellar lines. The drug, an acetylcholine release inhibitor and a neuromuscular blocking agent, achieved regulatory approval for this indication from both the US FDA and EU authorities earlier this year. The FDA also approved Dysport for cervical dystonia, and Ipsen will launch the product in the US later this year for this indication. The product has also been launched in the UK, as Azzalure, by Galderma, also for glabellar lines. In the UK, its wholesale price is £41 per 125 unit vial. The product has been marketed as Dysport in the UK by Ipsen since the 1990s for medical indications such as blepharospasm.
You may also be interested in...
Experimental drugs rarely face setbacks because they are too effective, but Pfizer's novel nerve growth factor antagonist tanezumab might number among the unlucky few. Phase II data presented this week in the NEJM show that the monoclonal antibody relieved osteoarthritic pain, but an accompanying editorial proposed that in doing so the analgesic enables physical activity that can lead to excessive wear and tear on fragile joints.
AstraZeneca has enrolled the first patient in the pivotal programme for the first-in-class Syk kinase inhibitor fostamatinib (previously known as R778). Fostamatinib, which it licensed from Rigel Pharmaceuticals, is being evaluated as a treatment for rheumatoid arthritis (RA) in patients with an inadequate response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX).
The Michael J. Fox foundation has launched a $40 million, 5-year initiative to identify biomarkers of Parkinson's disease progression. The scheme, called the Parkinson's Progression Markers Initiative (PPMI), will be carried out at 18 sites in the US and the EU, and will track 400 patients with newly diagnosed disease as well as 200 who do not have the disease.